Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Buys 10,000 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Paul Herendeen acquired 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the purchase, the director owned 111,687 shares of the company’s stock, valued at $2,644,748.16. The trade was a 9.83% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Elanco Animal Health Trading Up 0.6%

NYSE:ELAN traded up $0.14 during trading hours on Monday, hitting $22.26. 22,463,632 shares of the company were exchanged, compared to its average volume of 5,703,481. The stock has a market capitalization of $11.12 billion, a price-to-earnings ratio of -54.29, a price-to-earnings-growth ratio of 1.32 and a beta of 1.67. Elanco Animal Health Incorporated has a one year low of $16.89 and a one year high of $27.98. The company has a fifty day simple moving average of $24.70 and a 200 day simple moving average of $24.08. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Elanco Animal Health during the second quarter worth approximately $1,202,198,000. T. Rowe Price Investment Management Inc. lifted its stake in shares of Elanco Animal Health by 11.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after buying an additional 3,717,404 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Elanco Animal Health by 1.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock valued at $567,622,000 after buying an additional 373,869 shares in the last quarter. UBS Group AG grew its holdings in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Elanco Animal Health by 7.3% during the fourth quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock worth $213,343,000 after acquiring an additional 640,098 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 31st. Morgan Stanley increased their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. Citigroup boosted their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, TD Cowen raised their target price on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.09.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.